CancerVax CEO David F. Hale Receives Life Sciences Legend Award; Award Honors Lifetime Achievement Within the San Diego Life Sciences Industry.Business Editors/Health/Medical Writers BioFUSION Life Science Achievement and Innovation Awards CARLSBAD, Calif.--(BUSINESS WIRE)--June 20, 2003 CancerVax Corporation announced today that President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. David F. Hale was honored with the Life Sciences Legend Award at the third annual BioFUSION Life Science Achievement and Innovation Awards ceremony. The ceremony, which is sponsored by The T Sector and BIOCOM/sandiego, recognizes innovators and leaders who have contributed significantly to the growth and success of the San Diego life science industry. "Our judges selected David Hale for the Life Sciences Legend Award because of his lifelong commitment to the San Diego life science community," said Katherine Harrington, publisher of The T Sector, a magazine, Web site, email newsletter and events company focused on San Diego's high-tech and biotech industries. "For more than 20 years David has provided leadership and inspiration to the companies, industry organizations and individuals in our thriving local biotech industry." "I am honored to receive the BioFUSION Life Sciences Legend Award and feel privileged to be a part of San Diego's biotechnology community," said Mr. Hale. "San Diego's life science industry has experienced enormous success, and given the tenacity and dedication of the individuals I have had the pleasure of working alongside over the years, I have no doubt that we will weather the current economic storms and realize our goal of developing biotechnology products that extend and improve the quality of life of patients." In addition to his position as President, CEO and Board member of CancerVax Corporation, Mr. Hale currently serves on the board of directors for biotechnology companies Santarus, Inc., Metabasis Therapeutics, Inc., Xcel Pharmaceuticals, Inc., and SkinMedica, Inc. He is also Chairman of the board of directors for LMA LMA left mentoanterior (position of fetus). North America, Inc. and BIOCOM/sandiego (formerly the Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Industry Council), of which he was a founder. Mr. Hale also serves on the board of directors for the Emerging Growth Companies Section of the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
UCSD User Centered System Design UCSD Urbana-Champaign Sanitary District (Illinois) UCSD Ultra Cool Sexy Dudes CONNECT Program in Technology and Entrepreneurship, where he serves on the Leadership Council. An experienced biotech executive, Mr. Hale previously served as President of Hybritech, Inc., San Diego's first biotechnology company, which was acquired by Eli Lilly & Co. He was also previously Chairman, President, and CEO of Gensia, Inc. (now Sicor, Inc.), a co-founder and Chairman of Viagene, Inc., and President and CEO of Women First HealthCare, Inc. About CancerVax Corporation (www.cancervax.com) CancerVax Corporation is a privately held biotechnology company focused on the research, development and commercialization of biological products for the treatment and control of cancer. The Company's lead product candidate, CANVAXIN(TM), is a therapeutic cancer vaccine currently being evaluated in two international Phase 3 clinical trials phase 3 clinical trial Phase 3 study. See Phase study. for the treatment of advanced-stage melanoma. CancerVax also plans to evaluate the vaccine in the treatment of advanced-stage colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. and develop additional vaccines to treat other types of cancers. The FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has granted CancerVax both Orphan Drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the and Fast Track designations for the CANVAXIN(TM) vaccine in the treatment of metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. melanoma. The Company has additional product candidates in preclinical development for the treatment of cancer, including several monoclonal antibodies that appear to inhibit angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. , the blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. development that is necessary for tumor growth. CancerVax maintains its corporate headquarters in Carlsbad, California, and its biologics manufacturing facility in Los Angeles, California. CancerVax cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects Side effects Effects of a proposed project on other parts of the firm. or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CancerVax(R) and CANVAXIN(TM) are trademarks of CancerVax Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion